After 18 years in development, AstraZeneca’s CTLA-4 antibody gets the red carpet treatment at the FDA

After a decade, a second CTLA-4 antibody may finally be on its way to approval.

AstraZeneca announced Monday that the FDA had given priority review to tremelimumab, its long-gestating CTLA-4 antibody, in combination with the PD-1 inhibitor Imfinzi for patients with liver cancer that can’t be treated with surgery.